203 Users Online
Miscarriage Analysis market Segmented By Test such as Cytogenic analysis, Chromosomal microarray based analysis (CMA), Blood Test, Pelvic Ultrasound scan, Cervical weakness testing and Pre implantation genetic diagnosis
Miscarriage is referred to as spontaneous ending of a pregnancy. About half of the miscarriage appear within the first trimester earlier than 20 week’s gestation. Recurrent miscarriage remains to be challenging reproductive problem for the patient and clinician.
The statistical data demonstrates an expected 1 out of 4 pregnancies end in premature delivery, around 1 of every 100 ladies in the UK experience recurrent miscarriage, more than 6 out of 10 of women who have a recurrent miscarriage proceed to have successful pregnancy. Many miscarriage in the first trimester are caused by chromosomal abnormalities in the baby.
Miscarriage analysis testing, additionally called Products of Conception testing, is a subset of the general pre-birth testing market. It permits obstetrician and gynecologist, physicians, conceptive endocrinologists, fertility specialists and clinicians to more readily decide whether there is a hereditary reason for miscarriage or other related event.
Identification of cytogenetic factors for the miscarriage in the assessment of couples with history of recurrent miscarriage give rise in growth of miscarriage analysis market. Other critical factors are identification of antibodies, uterine abnormalities, hormonal & metabolic factors and infections are the important component for the growth of miscarriage analysis test market.
Increase in the risk factors for miscarriage includes previous miscarriage history, exposure to smoke, obesity, thyroid problems, diabetes, drug or alcohol use are the contributing factors in the growth of miscarriage analysis market. The other most common cause of miscarriage is chromosomal abnormality and other causes included hormonal changes, change in life style, maternal age, maternal trauma etc. are expected to be driving force in growth of miscarriage analysis market.
Careful assessment through miscarriage analysis with an examination of cytogenetic factor, restorative history and physical examination, ultrasonography and serum beta HCG testing can be useful in making a very certain diagnosis.
Not just cytogenetic of miscarriage analysis been demonstrated to be financially effective in the medicinal services framework but the outcomes help the gynecologist to choose for further examinations, bringing about time-investment funds to both the patient and the clinician, as well as cost-savings to the health care system.
Different reimbursement policy for the different types of miscarriage analysis test as conventional chromosomal analysis cannot be covered due to policy constraints could be a restraining factor for the growth of miscarriage analysis market.
The miscarriage analysis market is expected to be dominated by the North America due to higher prevalence of the clinical miscarriage case, increases awareness of miscarriage diagnosis, access to abortion providers and availability of information and healthcare. Europe is expected to be the second most lucrative region in the miscarriage analysis market.
Asia-Pacific is expected to be the fast growing miscarriage analysis market due to large population residing in countries such as India and China with attributes like shift in the economy and in attitude about preventive measures in the pregnancy care.
The key participants operating in the miscarriage analysis market are Igenomix, Natera, Integrated genetics, Invitae, VCGS, Quest diagnostics, MedlinePlus, Genomic diagnostics, Leeds Genetic Laboratory, Labassure and others.